Matches in Wikidata for { <http://www.wikidata.org/entity/Q37455633> ?p ?o ?g. }
- Q37455633 description "2012 թվականի օգոստոսի 10-ին հրատարակված գիտական հոդված" @default.
- Q37455633 description "article científic" @default.
- Q37455633 description "article scientifique" @default.
- Q37455633 description "articolo scientifico" @default.
- Q37455633 description "artigo científico" @default.
- Q37455633 description "artículu científicu espublizáu en 2012" @default.
- Q37455633 description "bilimsel makale" @default.
- Q37455633 description "bài báo khoa học" @default.
- Q37455633 description "scientific article published on 10 August 2012" @default.
- Q37455633 description "vedecký článok" @default.
- Q37455633 description "vetenskaplig artikel" @default.
- Q37455633 description "videnskabelig artikel" @default.
- Q37455633 description "vědecký článek" @default.
- Q37455633 description "wetenschappelijk artikel" @default.
- Q37455633 description "wissenschaftlicher Artikel" @default.
- Q37455633 description "наукова стаття, опублікована в серпні 2012" @default.
- Q37455633 description "научни чланак" @default.
- Q37455633 description "مقالة علمية نشرت في 10 أغسطس 2012" @default.
- Q37455633 name "Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?" @default.
- Q37455633 name "Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?" @default.
- Q37455633 name "Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?" @default.
- Q37455633 type Item @default.
- Q37455633 label "Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?" @default.
- Q37455633 label "Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?" @default.
- Q37455633 label "Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?" @default.
- Q37455633 prefLabel "Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?" @default.
- Q37455633 prefLabel "Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?" @default.
- Q37455633 prefLabel "Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?" @default.
- Q37455633 P1433 Q37455633-C635E132-F724-4D47-8EE6-17A7D24FFFC0 @default.
- Q37455633 P1476 Q37455633-AA175B11-6EDF-49B4-A2C4-008E6E1BAF39 @default.
- Q37455633 P2093 Q37455633-16DC65B4-EB87-4BB0-B3DB-A5446DBD69EB @default.
- Q37455633 P2093 Q37455633-597F65C0-943F-4B2E-AB70-1DA80C4CE5F6 @default.
- Q37455633 P2093 Q37455633-B9BA7DF3-B89C-4CC5-BF8E-C0E5F31332BB @default.
- Q37455633 P2093 Q37455633-B9E3DE4D-021B-4ED6-ABBD-1870032E1C4A @default.
- Q37455633 P2093 Q37455633-C66B46F6-5AC5-45FF-B591-88F14FB81908 @default.
- Q37455633 P2093 Q37455633-DA2504AC-E743-4EFD-A152-666E7B64771A @default.
- Q37455633 P2093 Q37455633-F09924BA-9690-412D-9FE7-7C4AD9D0AD17 @default.
- Q37455633 P2093 Q37455633-F0B57D9A-400D-4157-A751-06D997E6B4C8 @default.
- Q37455633 P2860 Q37455633-033AC4DF-D0D9-4808-9B2A-14698A46E992 @default.
- Q37455633 P2860 Q37455633-2B37DF3B-9CDE-4AAE-A7A9-0135E424F0CE @default.
- Q37455633 P2860 Q37455633-3BF1CF7C-57BB-4E81-ABA7-D3972FEC0770 @default.
- Q37455633 P2860 Q37455633-3C2D2BA4-2C32-4F9C-B03A-FB7FB260FFDC @default.
- Q37455633 P2860 Q37455633-5B379E1E-FE98-4A72-B545-2F644D340408 @default.
- Q37455633 P2860 Q37455633-6483FB75-1E32-45B2-B48E-EF21DE7D74FF @default.
- Q37455633 P2860 Q37455633-657E789C-7FCE-4D75-B8E2-145E36130915 @default.
- Q37455633 P2860 Q37455633-6ECFB61E-DCF9-4E71-AC81-C090EF4C37A5 @default.
- Q37455633 P2860 Q37455633-79B94A2A-BC21-4697-8F94-49DC9F72D4D1 @default.
- Q37455633 P2860 Q37455633-7BF1C531-07D5-44BC-954C-82065842014F @default.
- Q37455633 P2860 Q37455633-881F9987-EC82-403C-9712-43CE6D27A984 @default.
- Q37455633 P2860 Q37455633-8A73E1A1-99C6-4AFE-9BE1-8B0DF012A6BA @default.
- Q37455633 P2860 Q37455633-934ED7A9-0CC9-4436-A9B9-7ECA6530720A @default.
- Q37455633 P2860 Q37455633-A9AF41D8-BDBD-45DC-9FB5-AA3F4A840C48 @default.
- Q37455633 P2860 Q37455633-BD164417-C453-4E3E-A623-70F3AF8F6669 @default.
- Q37455633 P2860 Q37455633-D67018C8-C1AA-426D-917A-5BEF57915483 @default.
- Q37455633 P2860 Q37455633-FEF42E1E-FADC-419E-B103-4C351B38A614 @default.
- Q37455633 P304 Q37455633-C253A265-336E-422E-8E23-D7310C15D300 @default.
- Q37455633 P31 Q37455633-3145FE84-DBBA-4E00-8D45-C15F508E0D5B @default.
- Q37455633 P356 Q37455633-D95B062C-E964-4A1D-B176-F75BFA4DD9A8 @default.
- Q37455633 P407 Q37455633-AC42B08E-5BD8-47C9-8433-8D48A2223B80 @default.
- Q37455633 P433 Q37455633-01CDBDAB-D955-447B-8DB4-92143209CBC1 @default.
- Q37455633 P478 Q37455633-7FAC1D5F-17DE-4E79-974D-9CA801242695 @default.
- Q37455633 P50 Q37455633-BF4F5A51-19A7-4AE0-9319-D5CB52335E55 @default.
- Q37455633 P50 Q37455633-CDDE0B7F-1D11-4536-BB92-1A2C97080EA0 @default.
- Q37455633 P577 Q37455633-B26CFDC6-9B36-4956-8283-D4BD7C976867 @default.
- Q37455633 P698 Q37455633-DCEF68B2-C96C-4F85-B3D3-357C91EE0950 @default.
- Q37455633 P921 Q37455633-1FCA8221-BAA2-497A-BB97-B2F7894FEEDD @default.
- Q37455633 P921 Q37455633-6BA12A44-BDA8-4FEA-B184-B27704A31CE5 @default.
- Q37455633 P932 Q37455633-27BF0560-708C-4336-A04F-0CB0440588E5 @default.
- Q37455633 P356 J.YGYNO.2012.08.001 @default.
- Q37455633 P698 22885866 @default.
- Q37455633 P1433 Q5625182 @default.
- Q37455633 P1476 "Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?" @default.
- Q37455633 P2093 "Blair Smith" @default.
- Q37455633 P2093 "David M O'Malley" @default.
- Q37455633 P2093 "Eric Eisenhauer" @default.
- Q37455633 P2093 "Georgia A McCann" @default.
- Q37455633 P2093 "Jeffrey M Fowler" @default.
- Q37455633 P2093 "Kellie Rath" @default.
- Q37455633 P2093 "Ritu Salani" @default.
- Q37455633 P2093 "Simi Chacko" @default.
- Q37455633 P2860 Q27860904 @default.
- Q37455633 P2860 Q28258045 @default.
- Q37455633 P2860 Q34030022 @default.
- Q37455633 P2860 Q34981128 @default.
- Q37455633 P2860 Q36512803 @default.
- Q37455633 P2860 Q36540158 @default.
- Q37455633 P2860 Q36778998 @default.
- Q37455633 P2860 Q36822179 @default.
- Q37455633 P2860 Q40112553 @default.
- Q37455633 P2860 Q43700721 @default.
- Q37455633 P2860 Q43790301 @default.
- Q37455633 P2860 Q43865208 @default.
- Q37455633 P2860 Q44579933 @default.
- Q37455633 P2860 Q46529005 @default.
- Q37455633 P2860 Q53227029 @default.
- Q37455633 P2860 Q53300225 @default.
- Q37455633 P2860 Q82294729 @default.
- Q37455633 P304 "362-366" @default.
- Q37455633 P31 Q13442814 @default.
- Q37455633 P356 "10.1016/J.YGYNO.2012.08.001" @default.